Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Operating Expenses (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Operating Expenses for 6 consecutive years, with $26.4 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 29.3% to $26.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $146.1 million through Dec 2025, up 6.18% year-over-year, with the annual reading at $146.1 million for FY2025, 6.18% up from the prior year.
  • Operating Expenses for Q4 2025 was $26.4 million at TScan Therapeutics, down from $39.6 million in the prior quarter.
  • The five-year high for Operating Expenses was $41.7 million in Q2 2025, with the low at $9.9 million in Q1 2021.
  • Average Operating Expenses over 5 years is $26.9 million, with a median of $28.2 million recorded in 2023.
  • The sharpest move saw Operating Expenses skyrocketed 144.66% in 2021, then fell 29.3% in 2025.
  • Over 5 years, Operating Expenses stood at $17.1 million in 2021, then increased by 27.49% to $21.7 million in 2022, then skyrocketed by 31.38% to $28.6 million in 2023, then skyrocketed by 30.84% to $37.4 million in 2024, then dropped by 29.3% to $26.4 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $26.4 million, $39.6 million, and $41.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.